Camp4 Therapeutics (CAMP) Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. More details

CAMP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 61.23% per year

Revenue grew by 331.4% over the past year

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 10% per year for the next 3 years

Does not have meaningful revenue ($2M)

Volatile share price over the past 3 months compared to the US market

+ 2 more risks

CAMP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Camp4 Therapeutics Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Camp4 Therapeutics
Historical stock prices
Current Share Price	US$1.52
52 Week High	US$12.30
52 Week Low	US$1.31
Beta	0
1 Month Change	-23.23%
3 Month Change	-62.00%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-85.82%

Recent updates

Shareholder Returns

	CAMP	US Biotechs	US Market
7D	8.6%	0.1%	3.4%
1Y	n/a	-10.9%	13.7%

Return vs Industry: Insufficient data to determine how CAMP performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how CAMP performed against the US Market.

Price Volatility

Is CAMP's price volatile compared to industry and market?
CAMP volatility
CAMP Average Weekly Movement	15.7%
Biotechs Industry Average Movement	12.1%
Market Average Movement	7.7%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	4.0%

Stable Share Price: CAMP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CAMP's weekly volatility has decreased from 25% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2015	55	Josh Mandel-Brehm	www.camp4tx.com

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders.

Camp4 Therapeutics Corporation Fundamentals Summary

How do Camp4 Therapeutics's earnings and revenue compare to its market cap?
CAMP fundamental statistics
Market cap	US$30.64m
Earnings (TTM)	-US$51.77m
Revenue (TTM)	US$1.51m

20.3x

P/S Ratio

-0.6x

P/E Ratio

Is CAMP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAMP income statement (TTM)
Revenue	US$1.51m
Cost of Revenue	US$39.22m
Gross Profit	-US$37.71m
Other Expenses	US$14.06m
Earnings	-US$51.77m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.57
Gross Margin	-2,497.55%
Net Profit Margin	-3,428.61%
Debt/Equity Ratio	0.2%

How did CAMP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/29 06:22
End of Day Share Price	2025/06/27 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Camp4 Therapeutics Corporation is covered by 4 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eric Joseph	J.P. Morgan
Mani Foroohar	Leerink Partners LLC
Edward Tenthoff	Piper Sandler Companies